Biocontrol agents are the organisms or microorganisms that control the plant pathogen in turf grass. The global turf grass biocontrol agent market is segmented by form and geography. The report offers market size and forecast by value (USD million) for the above segments.

The scope of the report includes the application of vitamins and amino acids in food and beverage, pharmaceuticals, and animal feed industries across the globe.

The uterine fibroids market (henceforth referred to as the market studied unless specified otherwise) is estimated to be USD 4,564.8 million in 2024. It is expected to reach USD 6,927.7 million by 2029, registering a CAGR of 8.7% from 2024 to 2029 (henceforth referred to as the forecast period).

Bloomberg Law News - Amgen Seeks Speedy Ruling Against Colorado Drug Pricing Board - 26/6/2024 Drugmaker Amgen Inc. will suffer “concrete harm” unless a federal judge quickly enjoins Colorado’s drug pricing board from moving forward with a payment cap for the autoimmune treatment Enbrel, the company argued in a filing.

First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting Positive results from the ECHO Phase III trial showed AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and showed a favourable trend in overall survival (OS) compared to standard-of-care chemoimmunotherapy (bendamustine plus rituximab) in previously untreated patients with mantle cell lymphoma (MCL). These results will be presented today in a late-breaking oral presentation at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain (#LBA3439).

RAHWAY, N.J.–(3BL MEDIA)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Merck for Mothers, the company’s global maternal health initiative, has reached more than 30 million women through programs promoting safe, high-quality, respectful care, surpassing its goal of reaching 25 million women by 2025. Merck for Mothers supports the company’s work in expanding access to health and accelerating progress toward the United Nations’ Sustainable Development Goal 3 (SDG 3), which aims to ensure healthy lives and promote well-being for all. More specifically, the initiative is focused on creating a world where no woman has to die while giving life by helping to address the first target under SDG 3, reducing the global maternal mortality ratio to less than 70 per 100,000 live births by 2030.

Blood culture tests are diagnosis procedures that help to detect the presence of fungi and bacteria in the bloodstream. They are simple yet essential clinical tests that help identify and treat several infections. They offer valuable insights into overall health. In medical science, blood culture tests are used to check some types of foreign invaders that can be grown in controlled conditions. The presence of these microbes in the bloodstream can be a sign of blood infection, which is known as bacteremia. Generally, the tests comprise a simple blood sample that is analyzed in the laboratory, and medical professionals evaluate the findings to identify the origin of the infection and treatment. It is important to diagnose any blood infections because they can lead to severe complications, such as sepsis.

行情回顾:2024年1-10月，申万医药指数下跌11.19%，跑输沪深300指数23.4pp，年初以来医药行业涨跌幅排名第32。 2024年10月申万医药指数下跌4.32% ，跑输沪深300指数1.65pp，月初以来行业涨跌幅排名第28。2024年1-10月，原料药 累计涨幅最大(0.8%);线下药店累计跌幅最大(-35.3%)。2024年10月，原料药微跌(-2.2%)，血液制品涨幅最小(- 9.8%)。 创新药国谈和三季报落地。创新药国谈方向投资机会值得期待，此外医药三季报上市公司已全面落地。关于医疗器械板块， 2024年10月30日，安徽省医保局发布关于《二十七省(区、兵团)2024 年体外诊断试剂省际联盟集中带量采购文件(征求 意见稿)》公开征求意见的公告。安徽省医保局在国家医保局指导下即将开启省际联盟集采。集采品种为肿标16项(化学发 光、流式荧光、时间分辨免疫荧光 等)+甲功9项( 仅化学发光)。整体规 则与去年集采传染病和 性激素类似，其中肿标 和甲 功分别组套采购，大体分AB组，累计意向采购量前90%进A组，其余进B组，针对某些甲功试剂盒产品不足5项的进C组。此 次亦设有降幅50%保底线，相对比较温和。具体的报量情况及最高有效申报价要等后续文件。 重申2024年中期策略，我们看好医药板块下半年行情，重点看好低估值、出海、院内刚需三大主线。1)方向之一——红利 板块包括高股息OTC个股;国企改革预期相关板块值得关注。2)方向之二——器械出海包括IVD、呼吸机及呼吸道检测产品、 手套、冠脉支架等。创新药及类似物出海持续渐入佳境。3)方向之三——医疗反腐后，关注院内医疗刚性需求，比如血制 品、骨科、麻醉药、胰岛素、IVD、电生理等领域。消费医疗属性品种，以及上游等板块中长期值得跟踪。此外，上半年减 肥药和AI医疗主题投资性机会符合我们预期。

医药行业2024年三季报总结 Q3收入增速回正，利润有所承压

随着现代生活节奏的加快，睡眠问题已成为全球 重点关注的健康问题之一。睡眠问题影响个人生 活质量且可能引发一系列慢性疾病，对国民健康 造成严重威胁，科技创新正为睡眠健康和慢病管 理领域带来革命性变革。随着政策支持、技术升 级和国民健康意识的提升，睡眠经济正步入快速 发展期 睡眠监测类设备是用于监测和分析个体在睡眠过 程中的生理参数和睡眠质量的设备，通过收集和 分析睡眠相关的数据，帮助用户、医生或研究人 员了解睡眠状况。随着现代医学对睡眠疾病的认 识逐渐提高，睡眠监测技术得到越来越广泛的应 用，在神经科、呼吸科、耳鼻咽喉科、口腔科、 精神科等临床科室均有开展。应用场景从院内逐 步拓展到家用场景和其他便携式场景应用 本报告将对睡眠监测类设备的定义、应用领域、 产业链、各细分领域市场状况进行分析，以期对 市场未来发展方向做出研判